@article{f3c3f76cf8914418a701b294725b60bf,
title = "IL28B polymorphism does not determine outcomes of hepatitis B virus or HIV infection",
abstract = "An IL28B haplotype strongly determines the outcome of natural and interferon-α treated hepatitis C virus (HCV) infection. To assess whether the polymorphism marking the haplotype (rs12979860) also affects other interferon-α responsive chronic viral illnesses, namely hepatitis B virus (HBV) and human immunodeficiency virus (HIV) type 1 infections, we genotyped 226 individuals with HBV persistence, 384 with HBV recovery, and 2548 with or at high risk for HIV infection. The C/C genotype of rs12979860 was not associated with HBV recovery (odds ratio, 0.99), resistance to HIV infection (odds ratio, 0.97), or HIV disease progression (P > .05). This IL28B single-nucleotide polymorphism affects the immune response to HCV but not to HBV or HIV.",
author = "Martin, {Maureen P.} and Ying Qi and Goedert, {James J.} and Hussain, {Shehnaz K.} and Kirk, {Gregory D.} and Hoots, {W. Keith} and Susan Buchbinder and Mary Carrington and Thio, {Chloe L.}",
note = "Funding Information: The Multicenter Hemophilia Cohort Study is supported by the NCI (contract N02-CP-55504 with RTI International). The AIDS Link to Intravenous Experience (ALIVE) study is supported by the National Institute on Drug Abuse (grants R01-DA-04334 and R01-DA-12568). The Hemophilia Growth and Development Study is supported by the Bureau of Maternal and Child Health and Resources Development (MCJ-060570), the National Institute of Child Health and Human Development (NO1-HD-4–3200), the Centers for Disease Control and Prevention, and the National Institute of Mental Health. Funding Information: This work was supported by the Investigators in the Pathogenesis of Infectious Diseases Award from the Burroughs Wellcome Fund (C.L.T.). Data in this study were collected by the Multicenter AIDS Cohort Study (MACS), with centers (principal investigators) at the Johns Hopkins University Bloomberg School of Public Health (Joseph B. Margolick, Lisa Ja-cobson); Howard Brown Health Center and Northwestern University Medical School (John Phair); University of California, Los Angeles (Roger Detels); and University of Pittsburgh (Charles Rinaldo). The MACS is funded by the National Institute of Allergy and Infectious Diseases, with additional supplemental funding from the National Cancer Institute (NCI) and the National Heart, Lung and Blood Institute (grants UO1-AI-35042, 5-MO1-RR-00722 [GCRC], UO1-AI-35043, UO1-AI-37984, UO1-AI-35039, UO1-AI-35040, UO1-AI-37613, and UO1-AI-35041). Web site: http://www .statepi.jhsph.edu/macs/macs.html. Funding Information: Additional support has been provided by grants from the National Center for Research Resources of the National Institutes of Health (NIH) to the New York Hospital–Cornell Medical Center Clinical Research Center (grant MO1-RR06020), Mount Sinai General Clinical Research Center, New York (grant MO1-RR00071), University of Iowa Clinical Research Center (MO1-RR00059), and University of Texas Health Science Center, Houston (grant MO1-RR02558), and R01-HD-4–1224. This project has been funded in whole or in part with federal funds from the NCI, NIH (contract N01-CO-12400) and in part by the Intramural Research Program of the NIH, NCI, Center for Cancer Research.",
year = "2010",
month = dec,
day = "1",
doi = "10.1086/657146",
language = "English (US)",
volume = "202",
pages = "1749--1753",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "11",
}